The 41-year-old female, who was diagnosed with SLE 20 years ago, developed diffuse large B cell lymphoma (DLBCL), and was enrolled in a clinical trial using BCMA/CD19 dual-targeted CAR-T therapy due to side effects of standard R-CHOP chemotherapy. Here, TNFRSF17 is linked to diffuse large B-cell lymphoma.